Nuance Pharma Announces Acceptance for Review of the New Drug Application for Ohtuvayre® (ensifentrine) by the National Medical Products Administration of China for the maintenance treatment of chronic obstructive pulmonary disease

2026-01-27 - 02:32

SHANGHAI, Jan. 27, 2026 /PRNewswire/ — Nuance Pharma (“Nuance”) today announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA) for Ohtuvayre® (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease. Ohtuvayre® is a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (“PDE3 and